Brivudin induced delirium: a case report.
Ibak Gonen, Hakan Turan, Davud Ozdemir, Ahmet Sahin, Ayhan Sarıtas
Index: J. Chemother. 24(4) , 229-30, (2012)
Full Text: HTML
Abstract
Brivudin is an oral antiviral agent used to treat herpes zoster infections. Common side effects of brivudin include nausea and headache. This report describes delirium in a patient who used brivudin for herpes zoster treatment, which consequently remitted after drug cessation on the fourth day of medication use. To our knowledge, no such side effect has been reported to date. However, it is important that clinicians who prescribe brivudin are aware that treatment cessation is likely to result in total clinical recovery.
Related Compounds
Related Articles:
2012-07-01
[Biochem. J. 445(1) , 113-23, (2012)]
Synthesis of nucleoside-based antiviral drugs in ionic liquids.
2008-10-15
[Bioorg. Med. Chem. Lett. 18(20) , 5640-2, (2008)]
2010-01-01
[Nucleosides Nucleotides Nucleic Acids 29(1) , 1-13, (2010)]
Interaction between capecitabine and brivudin in a patient with breast cancer.
2010-01-01
[Nat. Rev. Clin. Oncol. 7(1) , 55-8, (2010)]
2011-08-01
[Med. Microbiol. Immunol. 200(3) , 193-202, (2011)]